01:50 , Mar 8, 2019 |  BC Innovations  |  Emerging Company Profile

Janpix picks STAT inhibitors for blood cancers

Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway. Janpix Inc. in-licensed its family of small...
18:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
22:49 , Feb 20, 2019 |  BC Extra  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Tuesday...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Mouse and guinea pig studies identified an inhalable JAK-1 inhibitor that could help treat asthma without the side effects of systemic JAK suppression. The inhalable compound is a previously reported pyrazolopyrimidine-based JAK-1 inhibitor...
22:26 , Nov 21, 2018 |  BC Extra  |  Preclinical News

Genentech develops inhalable JAK-1 inhibitor for asthma

Genentech Inc. scientists developed an inhalable Janus kinase-1 (JAK-1) inhibitor and suggested the small molecule could help treat asthma with a better safety profile than JAK inhibitors that act systemically. The Roche (SIX:ROG; OTCQX:RHHBY) unit...
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...